HypertensionRCTNCT04894344
Education to Decrease in Sodium Intake Evaluated With 24 Hour Urinary Sodium Excretion (RCT)
A study testing Education group in people with Hypertension and Overweight or Obesity, run by Universidad Autonoma de Baja California at 1 site in Mexico.
Trial summary
WHO identifies as an important risk factor and potentially modifiable to high sodium intake (>2g/day 5g salt/day). Also, an insufficient consumption of potassium ( 3.5 g/day).Therefore, the results of this research could be the regional basis that is required to generate evidence, that designs strategies and… Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypertension, Overweight or Obesity, Diabetes Mellitus, Type 2
- What is being tested?
- Education group
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 196 participants
- Where
- 1 siteMexico
- Study dates
- 28 Oct 2020to 9 May 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Young men and women 18-40 years of age with diastolic blood pressure <90 and systolic blood pressure < 130.
Who cannot join
- Chronic non-hypertensive diseases
- Physical disability
- Subjects under treatment with diuretics
- Pregnant women, lactating or in their menstrual cycle
- High performance athletes
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Naysin Yaheko Pardo Buitimea
Tijuana, Estado de Baja California, 22457
About this study
Official title: Education to Decrease in Sodium Intake in University Students Evaluated With 24 Hour Urinary Sodium Excretion: Randomized Controlled Trial
WHO identifies as an important risk factor and potentially modifiable to high sodium intake (>2g/day 5g salt/day). Also, an insufficient consumption of potassium ( 3.5 g/day).Therefore, the results of this research could be the regional basis that is required to generate evidence, that designs strategies and recommendations for the prevention or decrease in the progression of high blood pressure. The reduction in the consumption of salt in the diet could comply with the recommendations established by international agencies. In addition, to favor the beginning of lifestyle changes, as well as other modifications that will have a positive impact on health.In population highly vulnerable to the campaigns of large industries that favor the consumption of processed food.
However, it is unknown what is the effect of reducing foods high in sodium in populations in different regions of Mexico, estimated by 24 hour urine sodium excretion.
Read more
Therefore, the present study aims to answer the following questions:
What impact does an intervention aimed at the decrease in sodium intake, in young university students on blood pressure and the quantification of the excretion of sodium and urinary potassium of 24h? What is the association between body mass index, blood pressure and sodium reduction in the intervention vs control group? To assess the impact of an intervention aimed at reducing sodium intake through education as general recommendations for limiting specific foods high in sodium, in university students on blood pressure and quantification of urinary sodium and potassium excretion of 24h.
Specific objectives Assess sodium intake between the intervention group and the control group by estimating 24-hour urinary sodium excretion.
secundary objectives Evaluate the effect between the intervention group and the control group on blood pressure.
To assess the levels of potassium excretion in the intervention and control groups.
To evaluate the association between body mass index, blood pressure and sodium reduction in the intervention and control groups.
Read the detailed description
According to reports from the World Health Organization (WHO) in 2015, the prevalence of hypertension in the world is 1.13 billion people, representing 1 in 4 men and 1 in 5 women (WHO, 2019). In the Americas, every year 1.6 million people die from cardiovascular disease and it has been reported that 20-40% of the adult population suffer hypertension, representing 250 million people affected.
High salt intake (NaCl) is considered an essential risk factor in the development and progression of hypertension.In addition, several studies indicate that sodium in the diet is directly associated with blood pressure.Deleterious effects of high sodium intake associated with endothelial damage have also been reported in normotensive individuals independent of high blood pressure , reduced endothelial function and microvascular reactivity due to oxidative stress.Likewise, a decrease in the nitric oxide of the endothelium has been described that precedes the development of atherosclerotic plaques, which is known through a mechanism where nitric oxide inhibits platelet aggregation, the adhesion of platelets to collagen fibers and other adhesive proteins, as well as the stimulation of adipocyte hypertrophy by increasing the enzymatic activity of leptin and lipogenic enzymes .With type 2 diabetes mellitus (DM2) and increased insulin resistance through hemodynamic changes in the kidneys by sustained sodium reabsorption.In addition, high salt intake has also been associated with kidney disease, osteoporosis, kidney stone formation and stomach cancer.Recently, as a potential modulator of inflammatory and autoimmune diseases through direct and indirect mechanisms of cellular immunity.Therefore, international organizations recommend decreasing sodium intake in the diet. The WHO recommends that sodium intake be 2000 mg/d (equivalent to 5g of salt) and potassium intake 3.5 g/d in adults, to prevent chronic diseases such as hypertension, risk of heart disease and stroke.
Methodology Study design: a randomized controlled, parallel-group, prospective trial was conducted.
Sample: n= 114, undergraduate students from the Autonomous University of Baja California.
For the sample size of the comparison of two repeated averages in two different groups of participants.Public-Public Software was used for its calculationGRANMO developed by the URLEC Consortium of the research groups on Cardiovascular Risk and Nutrition and on Epidemiology and Cardiovascular Genetics of the IMIM-Hospital del Mar Research Program on Inflammatory and Cardiovascular Processes.
Variables Weight: To be measured with a scale brand TANITA Digital Body Fat Scale for Composition Monitor. Model BC-730F FitScan, (Tokyo, Japan), accurate to 0.1 Kg. Participants will be weighed with light clothing and without shoes.
Size: The size shall be measured without shoes and by the use of a SECA 213 (Hamburg, Germany) statistic, accurate to 0.1cm.
Body Mass Index (BMI): To be calculated according to the following formula: BMI= Weight (kg)/Size2 (cm). And it will be classified according to the criteria established by the WHO in: normal weight (18.5 to 25.0 kg/m2), overweight (25 to 30 kg/m2) and obesity ( 30 kg/m2).
Blood Pressure (BP): slope of the equipment (an automatic digital tensiometer validated for example OMRON will be used, according to the protocol for determining the sodium concentration.
Urinary excretion of sodium and potassium of 24h: It will be calculated by the method of selective electrons of ions in the Specialized Clinical Laboratory of Hematology and Transfusion Unit.
Intervention group Low sodium diet: Restriction of foods with high sodium content through educational newsletters once a week for 4 weeks control group Usual diet Age: 18- 30 years Gender: Male will be coded as 1, and female as 2 at the time of being captured in the database.
Weight: stage diagnosis according to body mass index, categories of normopeso, overweight or obesity according to the WHO.
Diagnosis of blood pressure: according to The eighth Joint National Committee guidelines (JNC 8) published in 2014.
Statistical Analysis: a sample size per group was calculated, with a statistical power of 80% to two tails, with a p= 0.05 to detect a difference of 1000 mg of sodium.A descriptive analysis shall be made of each of the variables expressed according to their level of measurement (averages or medians) with their respective dispersion measurement.
body mass index will be analyzed by category and sex for categorical data with the square Pearson's chi-squared test.
Correlation and simple linear regression shall be applied for body mass index, blood pressure and 24 hour sodium urinary excretion prior to the intervention.
The Student t test will be applied for related samples. Assumptions will be sought for parametric statistical analysis and the corresponding statistical test will be applied if the assumptions are met.The student t-test shall be applied for independent samples and mean differences in the intervention vs control group shall be analysed for 24-hour urinary sodium excretion data.The Kolmogorov-Smirnov test will be applied to see if there is a normal distribution.The Levene statistic shall be applied to assess homoscedasticityThe ANOVA test of a factor to analyze mean difference in the intervention group vs control group, in urinary sodium excretion by sex, will be applied.FACTORIAL ANOVA shall be applied to analyse mean difference in the intervention group vs control group in urinary sodium excretion (the same for potassium excretion) with the BMI categories, sex, for the categories of a low sodium diet (less 2000 mg of Na) and the categories of a standard sodium diet( greater than 3500 mg Na).
Procedure:
The study was submitted for authorization to the graduate committee of the Doctorate in Nutrition and Behavioral Sciences and to the ethics committee of the University Autonomous of Baja California.
Explanation of study purpose to participants and signature of informed consent. Details of how to collect the sample shall be given and the day and time of delivery indicated. A plastic canister with 24h urine collection capacity will be provided.
Blood pressure determination: Participants will be advised not to exercise, eat, drink, or smoke 30 minutes before taking their blood pressure. Before measuring the blood pressure, the participant will be asked to sit in a comfortable and quiet place for at least five minutes, with his back supported and without crossing his legs. When asking questions about behavior and personal medical history, just before taking the measurements, the participant should rest at least five minutes before starting the blood pressure test.
WHO recommends taking three blood pressure measurements. During data analysis, the average of the second and third readings is calculated. The participant must rest for one minute between each reading .
Heart rate measurement and recording should be done three times, along with blood pressure measurement and recording. The automatic tensiometer simultaneously presents the results.
The average of three measurements shall be calculated before the intervention and during the follow-up period.
24-hour urine collection: The urine sample will be collected in Plastic container: with capacity of three liters wide mouth BD Vacutainer, the second urine of the day until the first of the next morning. The sample shall be delivered on the agreed day for analysis.
The sodium in 24-hour urine excretion shall be estimated by selective ion electrode technology: the total sample shall be mixed, 200 μl shall be separated from the collected urine and diluted in 200 μl ml of urine diluent Urine thinner: (PN AV-BP0344D) company name and country of origin (if USA include state): Diluent used to analyze the urine sample in the electrolyte analyzer, (1:1 dilution). Select " urine mode" to analyze the sample. At the end, the results of the electrolytes Na, K and Cl will be reported on the screen. The result of the first measurement will be taken.They will be compared with the reference values, considering age and sex.
KontrolLab: Electrolyte Analyzer, KontroLab Analyzer is an in vitro diagnostic equipment manufactured with state-of-the-art technology, accurate, accurate and designed to be easy to use and maintain.
It is based on the properties of its transducers or sensors (electrodes) to be selective to a specific Ion in solution.
This is achieved thanks to the fact that the membranes of the Ion selective Electrodes develop a potential (with respect to a Reference electrode) proportional to the activity of the Ion in solution for which they are selective.
ISE Pack reagents: (PV AV-BP5186D) Include place of origin and company name: The package contains the following reagents for the calibration of sodium, potassium, chlorine, ionised calcium and lithium from the electrolyte analyser.
To obtain the value in mmol / 24 hours, it must be multiplied by the 24-hour sample volume of the patient, expressed in liters.
To blood pressure:
An automatic digital tensiometer validated according to the protocol for determining the sodium concentration, PAHO-WHO, 2010. It will be used marca OMRON: Model: HEM-7121.Distribuited by OMRON HEALTHCARE,INC.Illinois,U.S.A.
Intervention: They will be given recommendations for a low-sodium diet: Restriction of foods with high sodium content.
The duration time will be four weeks for assessment of BP and sodium excretion and consumption of foods high in salt; and at 24 weeks for the assessment of BP and consumption of foods high in salt.
Estimation of the consumption of fruits and vegetables,salt added to meals before and after meals and the consumption of industrialized products, at four and twenty-four weeks.
Physical activity and / or exercise will be assessed (type of exercise: aerobic or anaerobic and constancy: time 15 min, 30 min, 60 min, 120 min.
Questionnaire: identification of consumption fruits and vegetables, industrialized products, frequency, duration and type of exercise.
- Being tested
- Education group
- Keywords
- Collections, Urine Specimen, Diets, Healthy, Lifestyle, Mentoring, Planning,Health, Sodium,Dietary, Females, Males
- Medical subject headings
- Hypertension, Overweight, Obesity, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Education groupBehavioural
Is taught to choose low-sodium foods
| Study group | Role | What they receive |
|---|---|---|
| Educational program | Experimental | Participants will be randomly assigned. Intervention Group: 57 participants Each participant will receive the same educational information throughout the study, each week a newsletter will be provided with recommendations and information that teaches them to choose low-sodium foods for 4 weeks.
Urine samples of 24 h before and after the Intervention will be analyzed. Receives: Behavioral: Education group |
| Control group | No intervention | Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed. |
What is being measured
The primary outcome is the main question the study is designed to answer.
24-hour urine sodium excretion
mmol/l
Measured: up to 4 weeks
blood pressure
mmHg
Measured: up to 4 weeks
Secondary outcomes (2)
24-hour urine potassium excretion
mmol/l
Measured: up to 4 weeks
Physical activity
min
Measured: up to 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2021
- Study start28 Oct 2020
- Primary completion9 May 2023
- Study completion9 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (30)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two groups will be formed, the intervention group and the control group. Participants shall be randomly assigned to one of the two groups. Each patient group receives a single treatment simultaneously Urine measured 24 hours before and after the procedure as well as other variables of interest. The duration of the intervention will be 4 weeks.
- Masking
- None (open label)
- Enrolment
- 196 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Autonoma de Baja California
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Naysin Yaheko Pardo Buitimea, Universidad Autonoma de Baja California
- Investigators
- Arturo Jiménez-Cruz, Researcher, Study director, University Autonomus of Baja California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04894344
- Sponsor's protocol ID
- ArchiveBioethicsCommittee/245
- Acronym
- RCT
- Status last verified
- Dec 2023
- First submitted
- 27 Dec 2020
- Last updated
- 2 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected IPD, all IPD that underlie results in a publication
Publications
Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 Jun 18;73(23):3018-3026. doi: 10.1016/j.jacc.2019.03.507.
PubMed 31196460Forrester T, Adeyemo A, Soarres-Wynter S, Sargent L, Bennett F, Wilks R, Luke A, Prewitt E, Kramer H, Cooper RS. A randomized trial on sodium reduction in two developing countries. J Hum Hypertens. 2005 Jan;19(1):55-60. doi: 10.1038/sj.jhh.1001782.
PubMed 15470483Stamler J, Chan Q, Daviglus ML, Dyer AR, Van Horn L, Garside DB, Miura K, Wu Y, Ueshima H, Zhao L, Elliott P; INTERMAP Research Group. Relation of Dietary Sodium (Salt) to Blood Pressure and Its Possible Modulation by Other Dietary Factors: The INTERMAP Study. Hypertension. 2018 Apr;71(4):631-637. doi: 10.1161/HYPERTENSIONAHA.117.09928.
PubMed 29507099Weinberger MH. Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans. J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4):274-6. doi: 10.1111/j.1524-6175.2002.00924.x.
PubMed 12147930Drenjancevic-Peric I, Frisbee JC, Lombard JH. Skeletal muscle arteriolar reactivity in SS.BN13 consomic rats and Dahl salt-sensitive rats. Hypertension. 2003 May;41(5):1012-5. doi: 10.1161/01.HYP.0000067061.26899.3E. Epub 2003 Apr 7.
PubMed 12682080Drenjancevic-Peric I, Jelakovic B, Lombard JH, Kunert MP, Kibel A, Gros M. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34(1):1-11. doi: 10.1159/000320387. Epub 2010 Nov 12.
PubMed 21071956Larsen SC, Angquist L, Sorensen TI, Heitmann BL. 24h urinary sodium excretion and subsequent change in weight, waist circumference and body composition. PLoS One. 2013 Jul 25;8(7):e69689. doi: 10.1371/journal.pone.0069689. Print 2013.
PubMed 23936079Fonseca-Alaniz MH, Brito LC, Borges-Silva CN, Takada J, Andreotti S, Lima FB. High dietary sodium intake increases white adipose tissue mass and plasma leptin in rats. Obesity (Silver Spring). 2007 Sep;15(9):2200-8. doi: 10.1038/oby.2007.261.
PubMed 17890487Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med. 2010 Apr 20;152(8):481-7, W170-3. doi: 10.7326/0003-4819-152-8-201004200-00212. Epub 2010 Mar 1.
PubMed 20194225Vedovato M, Lepore G, Coracina A, Dodesini AR, Jori E, Tiengo A, Del Prato S, Trevisan R. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia. 2004 Feb;47(2):300-3. doi: 10.1007/s00125-003-1303-5. Epub 2003 Dec 24.
PubMed 14704836Wilck N, Balogh A, Marko L, Bartolomaeus H, Muller DN. The role of sodium in modulating immune cell function. Nat Rev Nephrol. 2019 Sep;15(9):546-558. doi: 10.1038/s41581-019-0167-y. Epub 2019 Jun 25.
PubMed 31239546Strazzullo P, Cairella G, Campanozzi A, Carcea M, Galeone D, Galletti F, Giampaoli S, Iacoviello L, Scalfi L; GIRCSI Working Group. Population based strategy for dietary salt intake reduction: Italian initiatives in the European framework. Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):161-6. doi: 10.1016/j.numecd.2011.10.004. Epub 2012 Feb 23.
PubMed 22364888Vega-Solano J, Blanco-Metzler A, Benavides-Aguilar KF, Arcand J. An Evaluation of the Sodium Content and Compliance with the National Sodium Reduction Targets among Packaged Foods Sold in Costa Rica in 2015 and 2018. Nutrients. 2019 Sep 15;11(9):2226. doi: 10.3390/nu11092226.
PubMed 31540146Manzel A, Muller DN, Hafler DA, Erdman SE, Linker RA, Kleinewietfeld M. Role of "Western diet" in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. 2014 Jan;14(1):404. doi: 10.1007/s11882-013-0404-6.
PubMed 24338487Cavka A, Cosic A, Jukic I, Jelakovic B, Lombard JH, Phillips SA, Seric V, Mihaljevic I, Drenjancevic I. The role of cyclo-oxygenase-1 in high-salt diet-induced microvascular dysfunction in humans. J Physiol. 2015 Dec 15;593(24):5313-24. doi: 10.1113/JP271631. Epub 2015 Dec 7.
PubMed 26498129
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Education to Decrease in Sodium Intake in University Students Evaluated With 24 Hour Urinary Sodium Excretion: Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04894344
- Acronym / sponsor ID
- RCT / ArchiveBioethicsCommittee/245
- Keywords
- Collections, Urine Specimen, Diets, Healthy, Lifestyle, Mentoring, Planning,Health, Sodium,Dietary, Females, Males
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 196 participants (actual)
- Lead sponsor
- Universidad Autonoma de Baja CaliforniaUniversity, hospital or other
- Study start
- 28 Oct 2020 (actual)
- Primary completion
- 9 May 2023 (actual)
- Study completion
- 9 May 2023 (actual)
- First posted
- 20 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
WHO identifies as an important risk factor and potentially modifiable to high sodium intake (>2g/day 5g salt/day). Also, an insufficient consumption of potassium ( 3.5 g/day).Therefore, the results of this research could be the regional basis that is required to generate evidence, that designs strategies and recommendations for the prevention or decrease in the progression of high blood pressure. The reduction in the consumption of salt in the diet could comply with the recommendations established by international agencies. In addition, to favor the beginning of lifestyle changes, as well as other modifications that will have a positive impact on health.In population highly vulnerable to the campaigns of large industries that favor the consumption of processed food.
However, it is unknown what is the effect of reducing foods high in sodium in populations in different regions of Mexico, estimated by 24 hour urine sodium excretion.
Therefore, the present study aims to answer the following questions:
What impact does an intervention aimed at the decrease in sodium intake, in young university students on blood pressure and the quantification of the excretion of sodium and urinary potassium of 24h? What is the association between body mass index, blood pressure and sodium reduction in the intervention vs control group? To assess the impact of an intervention aimed at reducing sodium intake through education as general recommendations for limiting specific foods high in sodium, in university students on blood pressure and quantification of urinary sodium and potassium excretion of 24h.
Specific objectives Assess sodium intake between the intervention group and the control group by estimating 24-hour urinary sodium excretion.
secundary objectives Evaluate the effect between the intervention group and the control group on blood pressure.
To assess the levels of potassium excretion in the intervention and control groups.
To evaluate the association between body mass index, blood pressure and sodium reduction in the intervention and control groups.
Detailed description
According to reports from the World Health Organization (WHO) in 2015, the prevalence of hypertension in the world is 1.13 billion people, representing 1 in 4 men and 1 in 5 women (WHO, 2019). In the Americas, every year 1.6 million people die from cardiovascular disease and it has been reported that 20-40% of the adult population suffer hypertension, representing 250 million people affected.
High salt intake (NaCl) is considered an essential risk factor in the development and progression of hypertension.In addition, several studies indicate that sodium in the diet is directly associated with blood pressure.Deleterious effects of high sodium intake associated with endothelial damage have also been reported in normotensive individuals independent of high blood pressure , reduced endothelial function and microvascular reactivity due to oxidative stress.Likewise, a decrease in the nitric oxide of the endothelium has been described that precedes the development of atherosclerotic plaques, which is known through a mechanism where nitric oxide inhibits platelet aggregation, the adhesion of platelets to collagen fibers and other adhesive proteins, as well as the stimulation of adipocyte hypertrophy by increasing the enzymatic activity of leptin and lipogenic enzymes .With type 2 diabetes mellitus (DM2) and increased insulin resistance through hemodynamic changes in the kidneys by sustained sodium reabsorption.In addition, high salt intake has also been associated with kidney disease, osteoporosis, kidney stone formation and stomach cancer.Recently, as a potential modulator of inflammatory and autoimmune diseases through direct and indirect mechanisms of cellular immunity.Therefore, international organizations recommend decreasing sodium intake in the diet. The WHO recommends that sodium intake be 2000 mg/d (equivalent to 5g of salt) and potassium intake 3.5 g/d in adults, to prevent chronic diseases such as hypertension, risk of heart disease and stroke.
Methodology Study design: a randomized controlled, parallel-group, prospective trial was conducted.
Sample: n= 114, undergraduate students from the Autonomous University of Baja California.
For the sample size of the comparison of two repeated averages in two different groups of participants.Public-Public Software was used for its calculationGRANMO developed by the URLEC Consortium of the research groups on Cardiovascular Risk and Nutrition and on Epidemiology and Cardiovascular Genetics of the IMIM-Hospital del Mar Research Program on Inflammatory and Cardiovascular Processes.
Variables Weight: To be measured with a scale brand TANITA Digital Body Fat Scale for Composition Monitor. Model BC-730F FitScan, (Tokyo, Japan), accurate to 0.1 Kg. Participants will be weighed with light clothing and without shoes.
Size: The size shall be measured without shoes and by the use of a SECA 213 (Hamburg, Germany) statistic, accurate to 0.1cm.
Body Mass Index (BMI): To be calculated according to the following formula: BMI= Weight (kg)/Size2 (cm). And it will be classified according to the criteria established by the WHO in: normal weight (18.5 to 25.0 kg/m2), overweight (25 to 30 kg/m2) and obesity ( 30 kg/m2).
Blood Pressure (BP): slope of the equipment (an automatic digital tensiometer validated for example OMRON will be used, according to the protocol for determining the sodium concentration.
Urinary excretion of sodium and potassium of 24h: It will be calculated by the method of selective electrons of ions in the Specialized Clinical Laboratory of Hematology and Transfusion Unit.
Intervention group Low sodium diet: Restriction of foods with high sodium content through educational newsletters once a week for 4 weeks control group Usual diet Age: 18- 30 years Gender: Male will be coded as 1, and female as 2 at the time of being captured in the database.
Weight: stage diagnosis according to body mass index, categories of normopeso, overweight or obesity according to the WHO.
Diagnosis of blood pressure: according to The eighth Joint National Committee guidelines (JNC 8) published in 2014.
Statistical Analysis: a sample size per group was calculated, with a statistical power of 80% to two tails, with a p= 0.05 to detect a difference of 1000 mg of sodium.A descriptive analysis shall be made of each of the variables expressed according to their level of measurement (averages or medians) with their respective dispersion measurement.
body mass index will be analyzed by category and sex for categorical data with the square Pearson's chi-squared test.
Correlation and simple linear regression shall be applied for body mass index, blood pressure and 24 hour sodium urinary excretion prior to the intervention.
The Student t test will be applied for related samples. Assumptions will be sought for parametric statistical analysis and the corresponding statistical test will be applied if the assumptions are met.The student t-test shall be applied for independent samples and mean differences in the intervention vs control group shall be analysed for 24-hour urinary sodium excretion data.The Kolmogorov-Smirnov test will be applied to see if there is a normal distribution.The Levene statistic shall be applied to assess homoscedasticityThe ANOVA test of a factor to analyze mean difference in the intervention group vs control group, in urinary sodium excretion by sex, will be applied.FACTORIAL ANOVA shall be applied to analyse mean difference in the intervention group vs control group in urinary sodium excretion (the same for potassium excretion) with the BMI categories, sex, for the categories of a low sodium diet (less 2000 mg of Na) and the categories of a standard sodium diet( greater than 3500 mg Na).
Procedure:
The study was submitted for authorization to the graduate committee of the Doctorate in Nutrition and Behavioral Sciences and to the ethics committee of the University Autonomous of Baja California.
Explanation of study purpose to participants and signature of informed consent. Details of how to collect the sample shall be given and the day and time of delivery indicated. A plastic canister with 24h urine collection capacity will be provided.
Blood pressure determination: Participants will be advised not to exercise, eat, drink, or smoke 30 minutes before taking their blood pressure. Before measuring the blood pressure, the participant will be asked to sit in a comfortable and quiet place for at least five minutes, with his back supported and without crossing his legs. When asking questions about behavior and personal medical history, just before taking the measurements, the participant should rest at least five minutes before starting the blood pressure test.
WHO recommends taking three blood pressure measurements. During data analysis, the average of the second and third readings is calculated. The participant must rest for one minute between each reading .
Heart rate measurement and recording should be done three times, along with blood pressure measurement and recording. The automatic tensiometer simultaneously presents the results.
The average of three measurements shall be calculated before the intervention and during the follow-up period.
24-hour urine collection: The urine sample will be collected in Plastic container: with capacity of three liters wide mouth BD Vacutainer, the second urine of the day until the first of the next morning. The sample shall be delivered on the agreed day for analysis.
The sodium in 24-hour urine excretion shall be estimated by selective ion electrode technology: the total sample shall be mixed, 200 μl shall be separated from the collected urine and diluted in 200 μl ml of urine diluent Urine thinner: (PN AV-BP0344D) company name and country of origin (if USA include state): Diluent used to analyze the urine sample in the electrolyte analyzer, (1:1 dilution). Select " urine mode" to analyze the sample. At the end, the results of the electrolytes Na, K and Cl will be reported on the screen. The result of the first measurement will be taken.They will be compared with the reference values, considering age and sex.
KontrolLab: Electrolyte Analyzer, KontroLab Analyzer is an in vitro diagnostic equipment manufactured with state-of-the-art technology, accurate, accurate and designed to be easy to use and maintain.
It is based on the properties of its transducers or sensors (electrodes) to be selective to a specific Ion in solution.
This is achieved thanks to the fact that the membranes of the Ion selective Electrodes develop a potential (with respect to a Reference electrode) proportional to the activity of the Ion in solution for which they are selective.
ISE Pack reagents: (PV AV-BP5186D) Include place of origin and company name: The package contains the following reagents for the calibration of sodium, potassium, chlorine, ionised calcium and lithium from the electrolyte analyser.
To obtain the value in mmol / 24 hours, it must be multiplied by the 24-hour sample volume of the patient, expressed in liters.
To blood pressure:
An automatic digital tensiometer validated according to the protocol for determining the sodium concentration, PAHO-WHO, 2010. It will be used marca OMRON: Model: HEM-7121.Distribuited by OMRON HEALTHCARE,INC.Illinois,U.S.A.
Intervention: They will be given recommendations for a low-sodium diet: Restriction of foods with high sodium content.
The duration time will be four weeks for assessment of BP and sodium excretion and consumption of foods high in salt; and at 24 weeks for the assessment of BP and consumption of foods high in salt.
Estimation of the consumption of fruits and vegetables,salt added to meals before and after meals and the consumption of industrialized products, at four and twenty-four weeks.
Physical activity and / or exercise will be assessed (type of exercise: aerobic or anaerobic and constancy: time 15 min, 30 min, 60 min, 120 min.
Questionnaire: identification of consumption fruits and vegetables, industrialized products, frequency, duration and type of exercise.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Two groups will be formed, the intervention group and the control group. Participants shall be randomly assigned to one of the two groups. Each patient group receives a single treatment simultaneously Urine measured 24 hours before and after the procedure as well as other variables of interest. The duration of the intervention will be 4 weeks.
| Arm | Type | Receives |
|---|---|---|
| Educational program | Experimental | Behavioral: Education groupParticipants will be randomly assigned. Intervention Group: 57 participants Each participant will receive the same educational information throughout the study, each week a newsletter will be provided with recommendations and information that teaches them to choose low-sodium foods for 4 weeks. Urine samples of 24 h before and after the Intervention will be analyzed. |
| Control group | No intervention | –Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Young men and women 18-40 years of age with diastolic blood pressure <90 and systolic blood pressure < 130.
Key exclusion criteria (5 listed)
- Chronic non-hypertensive diseases
- Physical disability
- Subjects under treatment with diuretics
- Pregnant women, lactating or in their menstrual cycle
- High performance athletes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Education groupIs taught to choose low-sodium foods | Behavioural | Educational program |
Primary outcome
24-hour urine sodium excretion
Time frame: up to 4 weeks
mmol/l
blood pressure
Time frame: up to 4 weeks
mmHg
2 secondary outcomes
24-hour urine potassium excretion
Time frame: up to 4 weeks
Physical activity
Time frame: up to 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2024.
- Results publication: PubMed 31196460Bakris G, Ali W, Parati G. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 Jun 18;73(23):3018-3026. doi: 10.1016/j.jacc.2019.03.507.
- Results publication: PubMed 15470483Forrester T, Adeyemo A, Soarres-Wynter S, Sargent L, Bennett F, Wilks R, Luke A, Prewitt E, Kramer H, Cooper RS. A randomized trial on sodium reduction in two developing countries. J Hum Hypertens. 2005 Jan;19(1):55-60. doi: 10.1038/sj.jhh.1001782.
- Results publication: PubMed 29507099Stamler J, Chan Q, Daviglus ML, Dyer AR, Van Horn L, Garside DB, Miura K, Wu Y, Ueshima H, Zhao L, Elliott P; INTERMAP Research Group. Relation of Dietary Sodium (Salt) to Blood Pressure and Its Possible Modulation by Other Dietary Factors: The INTERMAP Study. Hypertension. 2018 Apr;71(4):631-637. doi: 10.1161/HYPERTENSIONAHA.117.09928.
- Results publication: PubMed 12147930Weinberger MH. Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans. J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4):274-6. doi: 10.1111/j.1524-6175.2002.00924.x.
- Results publication: PubMed 12682080Drenjancevic-Peric I, Frisbee JC, Lombard JH. Skeletal muscle arteriolar reactivity in SS.BN13 consomic rats and Dahl salt-sensitive rats. Hypertension. 2003 May;41(5):1012-5. doi: 10.1161/01.HYP.0000067061.26899.3E. Epub 2003 Apr 7.
- Results publication: PubMed 21071956Drenjancevic-Peric I, Jelakovic B, Lombard JH, Kunert MP, Kibel A, Gros M. High-salt diet and hypertension: focus on the renin-angiotensin system. Kidney Blood Press Res. 2011;34(1):1-11. doi: 10.1159/000320387. Epub 2010 Nov 12.
- Results publication: PubMed 23936079Larsen SC, Angquist L, Sorensen TI, Heitmann BL. 24h urinary sodium excretion and subsequent change in weight, waist circumference and body composition. PLoS One. 2013 Jul 25;8(7):e69689. doi: 10.1371/journal.pone.0069689. Print 2013.
- Results publication: PubMed 17890487Fonseca-Alaniz MH, Brito LC, Borges-Silva CN, Takada J, Andreotti S, Lima FB. High dietary sodium intake increases white adipose tissue mass and plasma leptin in rats. Obesity (Silver Spring). 2007 Sep;15(9):2200-8. doi: 10.1038/oby.2007.261.
- Results publication: PubMed 20194225Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med. 2010 Apr 20;152(8):481-7, W170-3. doi: 10.7326/0003-4819-152-8-201004200-00212. Epub 2010 Mar 1.
- Results publication: PubMed 14704836Vedovato M, Lepore G, Coracina A, Dodesini AR, Jori E, Tiengo A, Del Prato S, Trevisan R. Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia. 2004 Feb;47(2):300-3. doi: 10.1007/s00125-003-1303-5. Epub 2003 Dec 24.
- Results publication: PubMed 31239546Wilck N, Balogh A, Marko L, Bartolomaeus H, Muller DN. The role of sodium in modulating immune cell function. Nat Rev Nephrol. 2019 Sep;15(9):546-558. doi: 10.1038/s41581-019-0167-y. Epub 2019 Jun 25.
- Results publication: PubMed 22364888Strazzullo P, Cairella G, Campanozzi A, Carcea M, Galeone D, Galletti F, Giampaoli S, Iacoviello L, Scalfi L; GIRCSI Working Group. Population based strategy for dietary salt intake reduction: Italian initiatives in the European framework. Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):161-6. doi: 10.1016/j.numecd.2011.10.004. Epub 2012 Feb 23.
- Pan American Health Organization: PAHO/WHOLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. All collected IPD, all IPD that underlie results in a publication
Related trials for Hypertension
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Not yet recruitingObservational study
Intra-Abdominal Pressure, Respiratory Mechanics, and Ventilator Liberation After Emergency Major Laparotomy
Intra-Abdominal Hypertension, Respiratory Mechanics
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
RecruitingObservational study
Natural History of Noncirrhotic Portal Hypertension
Cystic Fibrosis, Immunologic Deficiency Syndrome
RecruitingPhase 2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Pheochromocytoma, Paraganglioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arturo Jiménez-Cruz, Researcher study director
University Autonomus of Baja California
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Education group in people with Hypertension and Overweight or Obesity, run by Universidad Autonoma de Baja California at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
24-hour urine sodium excretion (time frame: up to 4 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04894344, which also lists 30 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2024.